In vitro and in vivo evaluation of the effects of duloxetine on P-gp function - PubMed (original) (raw)
. 2010 Nov;25(7-8):553-9.
doi: 10.1002/hup.1152.
Affiliations
- PMID: 21312289
- DOI: 10.1002/hup.1152
In vitro and in vivo evaluation of the effects of duloxetine on P-gp function
Zhao Ruike et al. Hum Psychopharmacol. 2010 Nov.
Abstract
Objective: To evaluate the effect of duloxetine (DLX) on the P-glycoprotein (P-gp) function in vitro and in vivo.
Method: In vitro experiment was conducted using the Caco-2 cell, a human colon cancer cell line that naturally expresses the P-gp and P-gp function was evaluated by monitoring whether DLX affect the accumulation of Rhd123. In vivo study was conducted by quantitating the effect of orally administered DLX on the bioavailability of talinolol.
Results: In the in vitro study, incubation of Caco-2 cell with DLX caused a concentration-dependent increase in the accumulation of Rhd123. In the in vivo study, co-administration of DLX increased the bioavailability of talinolol. The ratio (90% confidence intervals) of AUC(0-60), AUC(0-∞), and C(max) (talinolol alone versus talinolol plus DLX) were 0.87(0.77-1.06), 0.85(0.74-1.01), 0.87 (0.68-1.12).
Conclusion: Our results suggest that DLX could inhibit the function of P-gp in vitro and in vivo, and caution should be exercised when DLX is to be co-administered with drugs that are P-gp substrate.
Copyright © 2011 John Wiley & Sons, Ltd.
Similar articles
- P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound.
Spahn-Langguth H, Baktir G, Radschuweit A, Okyar A, Terhaag B, Ader P, Hanafy A, Langguth P. Spahn-Langguth H, et al. Int J Clin Pharmacol Ther. 1998 Jan;36(1):16-24. Int J Clin Pharmacol Ther. 1998. PMID: 9476144 - Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction.
Westphal K, Weinbrenner A, Zschiesche M, Franke G, Knoke M, Oertel R, Fritz P, von Richter O, Warzok R, Hachenberg T, Kauffmann HM, Schrenk D, Terhaag B, Kroemer HK, Siegmund W. Westphal K, et al. Clin Pharmacol Ther. 2000 Oct;68(4):345-55. doi: 10.1067/mcp.2000.109797. Clin Pharmacol Ther. 2000. PMID: 11061574 Clinical Trial. - Effect of continuous silymarin administration on oral talinolol pharmacokinetics in healthy volunteers.
Han Y, Guo D, Chen Y, Tan ZR, Zhou HH. Han Y, et al. Xenobiotica. 2009 Sep;39(9):694-9. doi: 10.1080/00498250903060077. Xenobiotica. 2009. PMID: 19555315 Clinical Trial. - Duloxetine Eli Lilly.
Anttila S, Leinonen E. Anttila S, et al. Curr Opin Investig Drugs. 2002 Aug;3(8):1217-21. Curr Opin Investig Drugs. 2002. PMID: 12211418 Review. - Human pharmacology of antidepressives.
Lader M. Lader M. Br J Clin Pharmacol. 1977;4Suppl 2(Suppl 2):135S-141S. doi: 10.1111/j.1365-2125.1977.tb05740.x. Br J Clin Pharmacol. 1977. PMID: 334215 Free PMC article. Review.
Cited by
- Precision Medicine in Antidepressants Treatment.
Tsermpini EE, Serretti A, Dolžan V. Tsermpini EE, et al. Handb Exp Pharmacol. 2023;280:131-186. doi: 10.1007/164_2023_654. Handb Exp Pharmacol. 2023. PMID: 37195310 Review. - Psychotropic drug-drug interactions involving P-glycoprotein.
Akamine Y, Yasui-Furukori N, Ieiri I, Uno T. Akamine Y, et al. CNS Drugs. 2012 Nov;26(11):959-73. doi: 10.1007/s40263-012-0008-z. CNS Drugs. 2012. PMID: 23023659 Review. - In vitro, in vivo, and in silico approaches for evaluating the preclinical DMPK profiles of ammoxetine, a novel chiral serotonin and norepinephrine reuptake inhibitor.
Zhu X, Li Y, Luo H, Zhang Y, Zhang Z, Li J. Zhu X, et al. Front Pharmacol. 2024 Nov 7;15:1486856. doi: 10.3389/fphar.2024.1486856. eCollection 2024. Front Pharmacol. 2024. PMID: 39575392 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous